Ovulation induction with human menopausal gonadotropins

Michael Peter Diamond, A. Colston Wentz

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

This review has summarized the evolution of hMG stimulation of ovulation in amenorrheic individuals, its monitoring, and its complications. Based on the principles learned from these individuals, use of hMG has now extended to women with cervical mucus deficiencies or luteal phase defects, as well as in vitro fertilization. Recommendations regarding the use of hMG at the current time when assessment by both serum E2 and ultrasound are available have been made. Briefly, it is suggested that an 'E2 window' of at least 1000 pg/ml be achieved over the course of a 9- to 12-day follicular phase. Furthermore, assessment of these monitoring modalities should be made in combination in order that findings from one modality alone not be allowed to initiate premature hCG administration.

Original languageEnglish (US)
Pages (from-to)480-490
Number of pages11
JournalObstetrical and Gynecological Survey
Volume41
Issue number8
StatePublished - Dec 1 1986
Externally publishedYes

Fingerprint

Menotropins
Cervix Mucus
Follicular Phase
Ovulation Induction
Luteal Phase
Fertilization in Vitro
Ovulation
Serum

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Ovulation induction with human menopausal gonadotropins. / Diamond, Michael Peter; Colston Wentz, A.

In: Obstetrical and Gynecological Survey, Vol. 41, No. 8, 01.12.1986, p. 480-490.

Research output: Contribution to journalReview article

@article{37cd2015405b42c48f5c7a70211696db,
title = "Ovulation induction with human menopausal gonadotropins",
abstract = "This review has summarized the evolution of hMG stimulation of ovulation in amenorrheic individuals, its monitoring, and its complications. Based on the principles learned from these individuals, use of hMG has now extended to women with cervical mucus deficiencies or luteal phase defects, as well as in vitro fertilization. Recommendations regarding the use of hMG at the current time when assessment by both serum E2 and ultrasound are available have been made. Briefly, it is suggested that an 'E2 window' of at least 1000 pg/ml be achieved over the course of a 9- to 12-day follicular phase. Furthermore, assessment of these monitoring modalities should be made in combination in order that findings from one modality alone not be allowed to initiate premature hCG administration.",
author = "Diamond, {Michael Peter} and {Colston Wentz}, A.",
year = "1986",
month = "12",
day = "1",
language = "English (US)",
volume = "41",
pages = "480--490",
journal = "Obstetrical and Gynecological Survey",
issn = "0029-7828",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Ovulation induction with human menopausal gonadotropins

AU - Diamond, Michael Peter

AU - Colston Wentz, A.

PY - 1986/12/1

Y1 - 1986/12/1

N2 - This review has summarized the evolution of hMG stimulation of ovulation in amenorrheic individuals, its monitoring, and its complications. Based on the principles learned from these individuals, use of hMG has now extended to women with cervical mucus deficiencies or luteal phase defects, as well as in vitro fertilization. Recommendations regarding the use of hMG at the current time when assessment by both serum E2 and ultrasound are available have been made. Briefly, it is suggested that an 'E2 window' of at least 1000 pg/ml be achieved over the course of a 9- to 12-day follicular phase. Furthermore, assessment of these monitoring modalities should be made in combination in order that findings from one modality alone not be allowed to initiate premature hCG administration.

AB - This review has summarized the evolution of hMG stimulation of ovulation in amenorrheic individuals, its monitoring, and its complications. Based on the principles learned from these individuals, use of hMG has now extended to women with cervical mucus deficiencies or luteal phase defects, as well as in vitro fertilization. Recommendations regarding the use of hMG at the current time when assessment by both serum E2 and ultrasound are available have been made. Briefly, it is suggested that an 'E2 window' of at least 1000 pg/ml be achieved over the course of a 9- to 12-day follicular phase. Furthermore, assessment of these monitoring modalities should be made in combination in order that findings from one modality alone not be allowed to initiate premature hCG administration.

UR - http://www.scopus.com/inward/record.url?scp=0022973520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022973520&partnerID=8YFLogxK

M3 - Review article

C2 - 3090489

AN - SCOPUS:0022973520

VL - 41

SP - 480

EP - 490

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

SN - 0029-7828

IS - 8

ER -